Clinical trials assessing the effects of GH treatment in patients with obesity have shown reductions in total adipose tissue mass, especially abdominal and visceral adipose tissue depots [3]. This evidence concerns the gene GH1 and obesity due to melanocortin 4 receptor deficiency.